?Evaluation the effects of Sitagliptin administration in patients with COVID-19
Phase 2
Recruiting
- Conditions
- Pneumonia of COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200420047147N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
Patients who diagnosed with COVID-19 by RT-PCR test
Oxygen saturation less than 93%
Age more than 18 years old
To sign the informed consent form
Exclusion Criteria
Chronic kidney disease
Acute kidney injury
Chronic liver disease
pregnancy or breastfeeding
Pancreatitis
Allergy to Sitagliptin
Pemphigus disease history
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fever. Timepoint: Daily, From admission to discharge time. Method of measurement: Thermometer.;Cough. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.;Dyspnea. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.
- Secondary Outcome Measures
Name Time Method Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Needs to mechanical ventilation. Timepoint: Daily,From admission to discharge time. Method of measurement: Medical Record.;Death. Timepoint: At end of the study. Method of measurement: Medical Record.